State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Abstract Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoub...
| 發表在: | Journal for ImmunoTherapy of Cancer |
|---|---|
| Main Authors: | , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
BMJ Publishing Group
2019-08-01
|
| 主題: | |
| 在線閱讀: | http://link.springer.com/article/10.1186/s40425-019-0686-x |
| _version_ | 1852799580753625088 |
|---|---|
| author | Richard Lemal Olivier Tournilhac |
| author_facet | Richard Lemal Olivier Tournilhac |
| author_sort | Richard Lemal |
| collection | DOAJ |
| container_title | Journal for ImmunoTherapy of Cancer |
| description | Abstract Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly explain the efficacy reported based on limited data for the first few series, and underlie the rationale of successive modulations in lymphodepletion schemes, transgene constructs, and, finally, the therapeutic association of CAR T cells with ibrutinib, which appears to be particularly promising. This review describes the published results and expected developments. |
| format | Article |
| id | doaj-art-71d7490b0ffa42fc84df207cbb264d03 |
| institution | Directory of Open Access Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2019-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| spelling | doaj-art-71d7490b0ffa42fc84df207cbb264d032025-08-19T20:40:36ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262019-08-01711610.1186/s40425-019-0686-xState-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019Richard Lemal0Olivier Tournilhac1Histocompatibility laboratory, CHU Clermont-Ferrand, INSERM CIC501, EA 7453 -Université Clermont AuvergneAdult Clinical Hematology, CHU Clermont-Ferrand, INSERM CIC501, EA 7453 -Université Clermont AuvergneAbstract Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly explain the efficacy reported based on limited data for the first few series, and underlie the rationale of successive modulations in lymphodepletion schemes, transgene constructs, and, finally, the therapeutic association of CAR T cells with ibrutinib, which appears to be particularly promising. This review describes the published results and expected developments.http://link.springer.com/article/10.1186/s40425-019-0686-xCLLCAR T cellsIbrutinib |
| spellingShingle | Richard Lemal Olivier Tournilhac State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 CLL CAR T cells Ibrutinib |
| title | State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 |
| title_full | State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 |
| title_fullStr | State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 |
| title_full_unstemmed | State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 |
| title_short | State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 |
| title_sort | state of the art for car t cell therapy for chronic lymphocytic leukemia in 2019 |
| topic | CLL CAR T cells Ibrutinib |
| url | http://link.springer.com/article/10.1186/s40425-019-0686-x |
| work_keys_str_mv | AT richardlemal stateoftheartforcartcelltherapyforchroniclymphocyticleukemiain2019 AT oliviertournilhac stateoftheartforcartcelltherapyforchroniclymphocyticleukemiain2019 |